The sanitary registration holder should not be the distributor. Country-by-country IOR rules and why bioaccess® holds registrations through its own entities, without commercial leverage.
The sanitary registration holder should not be the distributor. That is a design decision — not a branding preference — that determines whether a medical device manufacturer can change channels in Mexico, Brazil, Colombia, or Argentina without redoing the file. This article explains, at the rule level, why the local legal figure and the commercial channel have to live in separate entities, and why the bioaccess® LATAM Launch subscription exists: to register and sustain an FDA-cleared or CE-marked device through its own entities, with certified translations and government fees included, without turning the license into commercial leverage.
What the holder is — and what it is not
In Latin America the sanitary registration is issued in the name of a legal entity in the country. That entity is the titular, detentor, authorized representative, or holder, depending on the regulator. Technovigilance, responses to the authority, and — in several markets — importation fall on it. The distributor is a different function: it sells, invoices, and services. When both functions sit in the same company, the manufacturer does not have a channel. It has a partner that also owns the regulatory asset. Changing it means a rights assignment, a new registration, or both.
An independent holder — an own subsidiary or a professional holder that does not commercialize the product — makes it possible to name, add, or remove importers and distributors as each regulation allows. bioaccess® sustains registrations through its own local entities, for the manufacturer’s benefit, with assignment defined in the contract. The registration is not leverage. Country-by-country detail: Importer of Record in LATAM.
Countries with multiple importers on a single registration
These are the rules bioaccess® publishes in its IOR guide, with primary sources. They are not a consultancy ranking.
- Mexico (COFEPRIS). The Mexico Registration Holder can name multiple distributors and importers on a single sanitary registration. That is why an independent holder is useful and a distributor-holder is risky. Equivalence pathway for devices already authorized in a reference country (FDA, Health Canada, or Japan); CE marking alone does not qualify. See Mexico — COFEPRIS.
- Colombia (INVIMA). INVIMA expressly contemplates “one holder with multiple importers.” A Colombian legal face is required and, in practice, an importer with CCAA. The manufacturer does not have to give away title to the first commercializer. See Colombia — INVIMA.
- Brazil (ANVISA). RDC 751/2022 names a single registration detentor. RDC 270/2019 allows that detentor to authorize multiple importers without re-registering the device. The foreign manufacturer cannot be the detentor. A BRH that is not the exclusive importer is the correct design. See Brazil — ANVISA.
- Peru (DIGEMID). The holder must be an authorized droguería. Supreme Decree No. 001-2024-SA allows an independent Peru Registration Holder; other droguerías can obtain their own CRS. Again: holder ≠ commercial catalog.
- Costa Rica (Ministry of Health). Under Decreto N° 34482-S, the Costa Rica Registration Holder (titular) is a distinct legal entity from the importer of record. Multiple importers can be named on one registration, and the titular controls who gets added or removed — the same “license is not the channel” model. The titular must be domiciled in Costa Rica (local entity with cédula jurídica and a Costa Rican digital signature); a foreign manufacturer cannot hold directly.
- Chile (ISP), today. Most general devices fall outside the mandatory registration list; each importer processes its own CDA per shipment. The holder/authorized representative exists for the types that do register. The pending Fármacos II law will tighten the framework. See Chile — ISP.
Single registration-importer countries
In these markets the first holder choice is structural because the holder is the importer, or because the regulation names a single local representative:
- Argentina (ANMAT). The authorized representative is both holder and importer. One AAR per registration. Disposición 2318/2002 was repealed and replaced by Disposición 64/2025; the single-AAR-importer model remains the commercial fact. Changing AARs usually means re-registering. See Argentina — ANMAT.
- Ecuador (ARCSA). The certificate is issued in the holder’s name, an Ecuadorian company; a single holder (Resolution ARCSA-DE-026-2016-YMIH, as amended by ARCSA-DE-2023-033-AKRG).
- El Salvador (SRS). Since August 7, 2024 the Superintendencia de Regulación Sanitaria (successor to DNM) regulates devices; a single local legal representative per registration.
- Panama (DNDM / MINSA), Dominican Republic (DIGEMAPS), Paraguay (DINAVISA) and several Central American and Caribbean markets: single authorized representative model. Uruguay is not currently in bioaccess®’s published coverage.
The lesson is not “avoid local consultants.” The lesson is: in a single-IOR market, hosting under a professional holder’s own licenses (or bioaccess®’s entity) is what keeps the channel in the manufacturer’s hands. In a multiple-importer market, the same principle applies — only the mistake shows up later, when the first distributor blocks the second.
What the bioaccess® subscription includes — and what we don’t invent
bioaccess® registers and sustains devices already authorized by FDA (510(k)/PMA) or with CE marking. The flat annual fee per country and device family includes the sanitary registration, the holder / importer of record through its own entities, certified translations into Spanish or Portuguese (sworn where Brazil and Argentina require it), and government filing fees. Public coverage is 19 Latin American and Caribbean markets; there are country pages for Brazil, Mexico, Colombia, Argentina, and Chile. The Submission Guarantee covers what bioaccess® controls: a complete file, in certified language, with fees paid, on the committed date — or a credit against that country’s annual fee; terms in the proposal. bioaccess® clinical trial clients receive the published Trial-to-Market Bridge (20%). Specific fees are under review; request a quote. There are no invented prices in this article, no client lists, no third-party emails.
Two line items sit outside the flat fee because no credible party can flatten them: the BGMP plant audit in Brazil and the telecom/EMC-RF homologation for wireless devices. bioaccess® manages them and bills at supplier cost + 20% G&A, per the market access page.
bioaccess® is not the “single-country holder that also distributes.” It is the multi-country holder that is not the distributor. If the commercial plan is a single market and a local holder with its own entity is enough, that local holder is a valid product. If the plan is multiple seals under the same assignment doctrine, the subscription is the product that matches the rule — not the first result for “registro sanitario + [country].”
Next step: bioaccess® market access, the importer of record guide, or request a registration quote.
Leave a Reply